Literature DB >> 6971105

Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome.

A S Fauci, H M Moutsopoulos.   

Abstract

Numbers of B cells spontaneously secreting Ig (IgG, IgA, and IgM) were determined by a plaque-forming cell (PFC) assay simultaneously in the peripheral blood and bone marrow of normal individuals, patients with systemic lupus erythematosus (SLE), and patients with primary Sjögren's syndrome. Normal individuals had 382 (+/- 89) PFC per 10(6) mononuclear cells in peripheral blood. Patients with either active or inactive Sjögren's syndrome had normal numbers of spontaneous Ig-secreting cells in peripheral blood (P greater than 0.2). Conversely, patients with inactive as well as active SLE had markedly increased spontaneous PFC (P less than 0.05 and P less than 0.001, respectively). Patients with active SLE had significantly greater PFC than patients with inactive SLE; 3,984 (+/- 960) versus 1,605 (+/- 527) PFC per 10(6) mononuclear cells (P less than 0.05). The lack of increased numbers of activated B cells in the blood of patients with Sjögren's syndrome was not explained by a preferential sequestration of activated B cells in the bone marrow. However, of particular interest was the finding that the bone marrow served not only as a major source of virgin B cells but as a lymphoid organ of either in situ activation of B cells or sequestration for activated B cells. Normal individuals had approximately a 20-fold relative increase of activated B cells per 10(6) mononuclear cells in the bone marrow compared to peripheral blood, while patients with inactive and active SLE both had a 35-fold relative increase in activated B cells in bone marrow compared to peripheral blood. The potential relevance of circulating activated B cells and their sequestration in lymphoid organs is discussed concerning the discrepancy in this regard between Sjögren's syndrome and SLE, and our understanding of the significance of polyclonal B cell activation in the pathogenesis of these diseases.

Entities:  

Mesh:

Year:  1981        PMID: 6971105     DOI: 10.1002/art.1780240402

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

Review 2.  A conspicuous role for B cells In Sjögren's syndrome.

Authors:  Pierre Youinou; Valérie Devauchelle; Pascal Hutin; Rozenn Le Berre; Alain Saraux; Jacques-Olivier Pers
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis.

Authors:  Sarah Bradshaw; W Jim Zheng; Lam C Tsoi; Gary Gilkeson; Xian K Zhang
Journal:  Clin Immunol       Date:  2008-08-09       Impact factor: 3.969

4.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 5.  Genetic dissection of lupus nephritis in murine models of SLE.

Authors:  E K Wakeland; L Morel; C Mohan; M Yui
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

6.  Diminished response to an inhibitory signal in lymphocytes from patients with systemic lupus erythematosus.

Authors:  M Salata; J Golbus; B C Richardson
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

7.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

8.  Activation of peripheral blood lymphocytes in patients with primary Sjögren's syndrome.

Authors:  P Youinou; Y L Pennec; M A Blaschek; A Gentric; J Jouquan; A Lamour; P Angelidis
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

9.  Injection of mouse thyroglobulin and/or adult thymectomy do not break tolerance to thyroglobulin during the lupus like graft versus host disease in mice.

Authors:  F M van Rappard-van der Veen; Y M Kong; N R Rose; M Kimura; E Gleichmann
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.